Genzyme Corporation (NASDAQ:GENZ) added 0.36%
to $72.15. The company is expected to report third-quarter earnings of 54 cents
a share, according to a FactSet survey.
Over the
past 52-week, the stock had traded within the range of $45.39-$73.15 and is up
more than 45% year-to-date.
Gilead Sciences, Inc. (NASDAQ:GILD) went up
4% to $38.20. Late Tuesday, the company reported third-quarter net income rose
to $704.9 million, or 83 cents a share, from $673 million, or 72 cents, a year
ago.
Analysts
polled by FactSet Research, who typically exclude one-time items, predicted the
Foster City, Calif.-based biopharmaceutical company would earn 87 cents a share
on $1.93 billion in sales.
The
stock opened at $37.49 and has a 52-week range of $31.73-$49.50. In the past
one month of trading sessions, the stock went up more than 7%.
Cell
Therapeutics, Inc. (NASDAQ:CTIC) plunged 8.80% to $0.401. The
company announced that it has entered into an agreement to sell $21.0 million
of shares of its Series 7 Preferred Stock and warrants to purchase shares of
its common stock in a registered offering to four institutional investors.
The stock went down more than 65% year-to-date.
VIVUS, Inc. (NASDAQ:VVUS) lost 3.39%
to $5.84. VIVUS, Inc. is a biopharmaceutical company focused on the development
and commercialization of therapeutic products for underserved markets.
The
stock went down more than37% year-to-date.
Disclaimer: For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
